Company Active LTD

Company profile

Deltadot Limited

deltaDOT - deltaDOT Ltd

Deltadot Limited is a UK company with status active founded in 2000 based in London.

CRN
03949707
Founded
2000
Age
26

Overview

Legal name
DELTADOT LIMITED
Region
London
Registered address
LONDON BIOSCIENCE INNOVATION CENTRE
2 ROYAL COLLEGE STREET
LONDON
NW1 0NH
Insolvency history
No

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
4

Company events

Reference milestones and recent Companies House filing stream events.

9 events
27 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

27 Mar
2026

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzUxMjkyNjAwNmFkaXF6a2N4

Published 27 Mar 2026 08:15

26 Mar
2026

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzUxMjgxNDgxM2FkaXF6a2N4

Published 26 Mar 2026 17:50

26 Mar
2026

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzUxMjgxMzI0MmFkaXF6a2N4

Published 26 Mar 2026 17:30

13 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

25 Sep
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNzIyNDk5N2FkaXF6a2N4

Published 25 Sep 2024 04:06

13 Mar
2000

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2012
Funded years
2012, 2013
Age at first award
12 years

Projects

2013 Collaborative R&D Lead participant

Development of rapid and low-cost tool for biopharmaceutical formulation screening

1 Sep 2013 to 30 Nov 2014

Awarded
£76,947
Total cost £128,667

The project will bring an enabling platform technology that has been previously developed in 2012 TSB-funded feasibility study, to demonstrator stage. The demonstrator will address an unmet need in biopharmaceutical manufacturing industry, namely a cost-effective, user-friendly, automated system that will allow rapid screening for protein interaction lead...

2012 Feasibility Studies Lead participant

Rapid low cost formulation screening for protein self-interaction based on High Performance Capillary Electrophoresis

1 Aug 2012 to 30 Nov 2012

Awarded
£24,375
Total cost £32,500

The advance in protein-based biopharmaceuticals represents the most innovative and lucrative development in the pharmaceutical industry. Treatment with mAbs has evolved from former high mortality diseases like cancer into modern day chronic illness, including Alzheimer’s disease, lupus, diabetes and chronic pain. With the increased need for biopharmaceuti...

Product types

Collaborative R&D Feasibility Studies